Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. VNDA
stocks logo

VNDA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
59.28M
+11.45%
-0.963
+1103.13%
61.47M
+22.83%
-0.427
-14.67%
64.93M
+23.47%
-0.400
-13.04%
Estimates Revision
The market is revising Downward the revenue expectations for Vanda Pharmaceuticals Inc. (VNDA) for FY2025, with the revenue forecasts being adjusted by -2.97% over the past three months. During the same period, the stock price has changed by 12.07%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.97%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+27.72%
In Past 3 Month
Stock Price
Go Up
up Image
+12.07%
In Past 3 Month
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 5.200
sliders
Low
11.00
Averages
15.50
High
20.00
Current: 5.200
sliders
Low
11.00
Averages
15.50
High
20.00
Truist
Joon Lee
Hold
maintain
$20 -> $36
2025-11-10
Reason
Truist
Joon Lee
Price Target
$20 -> $36
2025-11-10
maintain
Hold
Reason
Truist analyst Joon Lee raised the firm's price target on AnaptysBio (ANAB) to $36 from $20 and keeps a Hold rating on the shares. The company's Q3 benefitted from $50M in Jemperli milestones and growing royalties, with another $75M in milestones expected in Q4, the analyst tells investors in a research note. Near-term catalysts for the stock include Phase 2 UC update in November-December and Vanda's (VNDA) imsidolimab BLA submission in Q4 for GPP, which is tied to milestones for AnaptysBio, the firm added.
B. Riley
NULL -> Buy
initiated
$11
2025-11-05
Reason
B. Riley
Price Target
$11
2025-11-05
initiated
NULL -> Buy
Reason
B. Riley initiated coverage of Vanda Pharmaceuticals with a Buy rating and $11 price target. The firm says Vanda is a commercial-stage turnaround story trading at a "historic discount." The company is heading into two potential approvals within three months and "clearing of multiple overhangs that have kept investors on the sidelines," the analyst tells investors in a research note. It believes the stock's current negative enterprise value represents an attractive entry point.
Cantor Fitzgerald
Overweight
initiated
$13
2025-05-14
Reason
Cantor Fitzgerald
Price Target
$13
2025-05-14
initiated
Overweight
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$20
2025-04-01
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$20
2025-04-01
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Maintains
$18 → $20
2025-02-18
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18 → $20
2025-02-18
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$18
2025-02-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$18
2025-02-04
Reiterates
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Vanda Pharmaceuticals Inc (VNDA.O) is -2.46, compared to its 5-year average forward P/E of -18.97. For a more detailed relative valuation and DCF analysis to assess Vanda Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-18.97
Current PE
-2.46
Overvalued PE
157.14
Undervalued PE
-195.08

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
4.81
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
11.51
Undervalued EV/EBITDA
-1.88

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.98
Current PS
0.00
Overvalued PS
2.81
Undervalued PS
1.14
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

VNDA News & Events

Events Timeline

(ET)
2025-12-04
16:30:00
Vanda Pharmaceuticals FDA Lifts Clinical Hold on Tradipitant
select
2025-11-28 (ET)
2025-11-28
07:02:31
Vanda Pharmaceuticals Offers Update on Tradipitant Regulatory Status
select
2025-11-17 (ET)
2025-11-17
18:41:24
Vanda Pharmaceuticals' tradipitant demonstrates promising outcomes for nausea and vomiting relief.
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
01:51 AMSeekingAlpha
PinnedVanda Soars After FDA Removes Partial Clinical Hold on Tradipitant

  • FDA Lifts Clinical Hold: Vanda Pharmaceuticals' tradipitant for motion sickness has seen a ~7% surge in after-hours trading after the FDA lifted its partial clinical hold, deeming the drug suitable for acute therapy without the need for additional toxicity studies.

  • Safety Concerns Addressed: The initial hold was due to safety concerns and insufficient chronic toxicity data, but the FDA concluded that motion sickness is an acute condition, allowing for the continuation of tradipitant's development.

  • Upcoming Decision on NDA: The FDA is expected to make a decision on a New Drug Application (NDA) for tradipitant aimed at preventing vomiting caused by nausea by December 30.

  • Potential Impact on Nausea Treatment: Vanda's tradipitant has shown promise in significantly reducing nausea in patients taking GLP-1 medications, highlighting its potential therapeutic benefits.

[object Object]
Preview
9.0
06:10 AMNewsfilter
Vanda Pharmaceuticals Lifts FDA Clinical Hold on Tradipitant, Advancing Drug Development
  • Clinical Hold Lifted: Vanda Pharmaceuticals announced that the FDA has lifted the partial clinical hold on protocol VP-VLY-686-3403, increasing the dose limit for tradipitant from 90 doses, marking a significant advancement in the treatment of motion sickness.
  • Accelerated Review Process: The lifting of the hold followed Vanda's formal dispute resolution request, with the FDA conducting an expedited re-review under the collaborative framework established in October 2025, demonstrating the effectiveness of their partnership.
  • New Drug Application Progress: Vanda's New Drug Application (NDA) for tradipitant, aimed at preventing vomiting induced by motion, is on track for review completion by December 30, 2025, potentially making it the first new pharmacologic treatment for motion sickness in over 40 years, highlighting its significant market potential.
  • Strengthened Strategic Collaboration: Vanda's CEO, Mihael H. Polymeropoulos, emphasized that the swift FDA review underscores the effectiveness of their collaboration, and the company looks forward to continued constructive dialogue to further drive innovation in the biopharmaceutical sector.
[object Object]
Preview
9.0
05:41 AMPRnewswire
Vanda Pharmaceuticals Lifts FDA Clinical Hold on Tradipitant, Advancing Drug Development
  • Clinical Hold Lifted: Vanda Pharmaceuticals announced that the FDA has lifted the partial clinical hold on protocol VP-VLY-686-3403, allowing for an increase in the maximum doses of tradipitant from 90, marking significant progress in the treatment of motion sickness and expected to accelerate clinical research efforts.
  • Accelerated Review Process: Following Vanda's formal dispute resolution request, the FDA swiftly re-reviewed and agreed that tradipitant's use for motion sickness represents an acute therapy, eliminating the need for an additional six-month dog toxicity study, which significantly shortens the timeline for potential drug approval.
  • New Drug Application Progress: Vanda's New Drug Application (NDA) for tradipitant targeting vomiting induced by motion is on track for a final FDA decision by December 30, 2025, and if approved, it will be the first new pharmacologic treatment for motion sickness in over 40 years, presenting substantial market potential.
  • Effective Collaborative Framework: Vanda's CEO Mihael H. Polymeropoulos highlighted the effectiveness of their collaborative framework with the FDA in facilitating scientific review, indicating a commitment to ongoing constructive dialogue that will enhance the company's competitive position in the biopharmaceutical sector.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Vanda Pharmaceuticals Inc (VNDA) stock price today?

The current price of VNDA is 5.2 USD — it has decreased -1.33 % in the last trading day.

arrow icon

What is Vanda Pharmaceuticals Inc (VNDA)'s business?

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

arrow icon

What is the price predicton of VNDA Stock?

Wall Street analysts forecast VNDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VNDA is 15.50 USD with a low forecast of 11.00 USD and a high forecast of 20.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Vanda Pharmaceuticals Inc (VNDA)'s revenue for the last quarter?

Vanda Pharmaceuticals Inc revenue for the last quarter amounts to 56.26M USD, increased 18.06 % YoY.

arrow icon

What is Vanda Pharmaceuticals Inc (VNDA)'s earnings per share (EPS) for the last quarter?

Vanda Pharmaceuticals Inc. EPS for the last quarter amounts to -0.38 USD, increased 322.22 % YoY.

arrow icon

What changes have occurred in the market's expectations for Vanda Pharmaceuticals Inc (VNDA)'s fundamentals?

The market is revising Downward the revenue expectations for Vanda Pharmaceuticals Inc. (VNDA) for FY2025, with the revenue forecasts being adjusted by -2.97% over the past three months. During the same period, the stock price has changed by 12.07%.
arrow icon

How many employees does Vanda Pharmaceuticals Inc (VNDA). have?

Vanda Pharmaceuticals Inc (VNDA) has 368 emplpoyees as of December 05 2025.

arrow icon

What is Vanda Pharmaceuticals Inc (VNDA) market cap?

Today VNDA has the market capitalization of 307.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free